Literature DB >> 22451217

Profile of eicosanoids in breath condensate in asthma and COPD.

Leandro Genehr Fritscher1, Martin Post, Marcelo Tadday Rodrigues, Frances Silverman, Mayer Balter, Kenneth R Chapman, Noe Zamel.   

Abstract

The collection of exhaled breath condensates (EBC) is a noninvasive method for obtaining samples from the lungs. Eicosanoids are lipid mediators implicated in the asthmatic inflammatory response. The objective of our study was to investigate whether the profile of eicosanoid lipid mediators in EBC can characterize the inflammation in asthma and chronic obstructive pulmonary disease (COPD). EBC samples were collected from 22 healthy controls (C), 25 mild intermittent asthmatics (MIA), 20 with moderate to severe asthma (MSA) and 20 with moderate to severe COPD. EBC samples were analyzed by unique tandem mass spectrometry that allows the quantification of up to 25 eicosanoid mediators simultaneously. No differences were found between MIA and C. Subjects with MSA and COPD had higher levels of 6-keto, PGE2, LTB4, 11-12 EET and AA, while lower levels of LXA4, 11DHyTxB2, 11HETE and 8,9EET, when compared to MSA and C (p < 0.05). Our study shows that the analysis of EBC through mass spectrometry is mixed and has a similar response in MSA and COPD when compared to MIA and controls.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22451217     DOI: 10.1088/1752-7155/6/2/026001

Source DB:  PubMed          Journal:  J Breath Res        ISSN: 1752-7155            Impact factor:   3.262


  16 in total

1.  Portable exhaled breath condensate metabolomics for daily monitoring of adolescent asthma.

Authors:  Alexander J Schmidt; Eva Borras; Anh P Nguyen; Danny Yeap; Nicholas J Kenyon; Cristina E Davis
Journal:  J Breath Res       Date:  2020-01-23       Impact factor: 3.262

Review 2.  Bronchoprotective mechanisms for specialized pro-resolving mediators in the resolution of lung inflammation.

Authors:  Melody G Duvall; Thayse R Bruggemann; Bruce D Levy
Journal:  Mol Aspects Med       Date:  2017-05-17

3.  Neu-164 and Neu-107, two novel antioxidant and anti-myeloperoxidase compounds, inhibit acute cigarette smoke-induced lung inflammation.

Authors:  Thomas H Thatcher; Hsi-Min Hsiao; Elhanan Pinner; Moshe Laudon; Stephen J Pollock; Patricia J Sime; Richard P Phipps
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-05-17       Impact factor: 5.464

4.  Exhaled breath condensate eicosanoid levels associate with asthma and its severity.

Authors:  Shamsah Kazani; Anna Planaguma; Emiko Ono; Matteo Bonini; Muhammad Zahid; Gautham Marigowda; Michael E Wechsler; Bruce D Levy; Elliot Israel
Journal:  J Allergy Clin Immunol       Date:  2013-04-19       Impact factor: 10.793

5.  Resolvins attenuate inflammation and promote resolution in cigarette smoke-exposed human macrophages.

Authors:  Amanda Croasdell; Thomas H Thatcher; R Matthew Kottmann; Romain A Colas; Jesmond Dalli; Charles N Serhan; Patricia J Sime; Richard P Phipps
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-08-21       Impact factor: 5.464

Review 6.  DHA- and EPA-derived resolvins, protectins, and maresins in airway inflammation.

Authors:  Melody G Duvall; Bruce D Levy
Journal:  Eur J Pharmacol       Date:  2015-11-03       Impact factor: 4.432

Review 7.  Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics.

Authors:  John D Imig
Journal:  Pharmacol Ther       Date:  2018-06-30       Impact factor: 12.310

8.  An investigation of the resolution of inflammation (catabasis) in COPD.

Authors:  Aina Noguera; Cristina Gomez; Rosa Faner; Borja Cosio; Ana González-Périz; Joan Clària; Angel Carvajal; Alvar Agustí
Journal:  Respir Res       Date:  2012-11-13

9.  Resolvin D1 and Resolvin E1 Promote the Resolution of Allergic Airway Inflammation via Shared and Distinct Molecular Counter-Regulatory Pathways.

Authors:  Bruce D Levy
Journal:  Front Immunol       Date:  2012-12-28       Impact factor: 7.561

Review 10.  The role of epoxyeicosatrienoic acids in the cardiovascular system.

Authors:  L Yang; K Mäki-Petäjä; J Cheriyan; C McEniery; I B Wilkinson
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.